News from the healthcare data industry
This engagement is designed to help Bristol Myers Squibb unlock new insights about long-term, real-world patient experiences within the DISCOVER-HCM Registry November 10, 2022 09:00 AM Eastern Standard Time SAN...
November 10, 2022 09:00 AM Eastern Standard Time SAN FRANCISCO–(BUSINESS WIRE)–Today, Komodo Health announced a collaboration with Intercept Pharmaceuticals (Nasdaq: ICPT), powering clinical research and new real-world evidence with Komodo’s...
Real world database fosters innovation for vulnerable populations November 08, 2022 09:00 AM Eastern Standard Time MISSISSAUGA, Ontario–(BUSINESS WIRE)–PointClickCare Technologies, a leading healthcare technology platform enabling meaningful collaboration and access...
– Using Invitae’s Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – Real-world insights...
GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library...
October 06, 2022 10:30 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test...
The first Fully Digital, Clinical Trial Solution for Oncology, Hematology & Urology CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ — ConcertAI, LLC (ConcertAI) announced the launch of its new Digital Trial Software-as-a-Service solution. Powered...
TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ —CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer. “The...
New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive Results From the Phase 3 DISCREET Study, Investigating...
August 10, 2022 04:02 PM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication...